What is the consensus of the medical community regarding Bextra?
Studies suggesting possible dangerous side effects of COX-2 inhibitors such as Bextra remain inconclusive and even contradictory. However, there is enough evidence that the FDA has made the following interim recommendations: Physicians prescribing Celebrex or Bextra , should consider this information when weighing the benefits against risks for individual patients. Patients who are at a high risk of gastrointestinal bleeding, have a history of intolerance to non-selective nonsteroidal anti-inflammatory drugs (NSAIDs), or are not doing well on non-selective NSAIDs may be appropriate candidates for COX-2 selective agents. Risk for cardiovascular events and other risks commonly associated with NSAIDs should be taken into account on an individual basis.
